CN115403644B - 一种烟碱甲氨基或氨基阿维菌素B1a化合物及其制备方法和应用 - Google Patents

一种烟碱甲氨基或氨基阿维菌素B1a化合物及其制备方法和应用 Download PDF

Info

Publication number
CN115403644B
CN115403644B CN202211065978.7A CN202211065978A CN115403644B CN 115403644 B CN115403644 B CN 115403644B CN 202211065978 A CN202211065978 A CN 202211065978A CN 115403644 B CN115403644 B CN 115403644B
Authority
CN
China
Prior art keywords
compound
mmol
methylamino
abamectin
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211065978.7A
Other languages
English (en)
Other versions
CN115403644A (zh
Inventor
史兰香
史建国
贾俊礼
张志辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shijiazhuang University
Original Assignee
Shijiazhuang University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang University filed Critical Shijiazhuang University
Priority to CN202211065978.7A priority Critical patent/CN115403644B/zh
Publication of CN115403644A publication Critical patent/CN115403644A/zh
Application granted granted Critical
Publication of CN115403644B publication Critical patent/CN115403644B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01PBIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P7/00Arthropodicides
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01PBIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P7/00Arthropodicides
    • A01P7/04Insecticides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Insects & Arthropods (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明公开了一种烟碱甲氨基或氨基阿维菌素B1a化合物。本发明的烟碱甲氨基或氨基阿维菌素B1a化合物具有杀虫活性,可用于制备杀虫剂中的用途。本发明公开了其制备方法。

Description

一种烟碱甲氨基或氨基阿维菌素B1a化合物及其制备方法和 应用
技术领域
本发明涉及烟碱甲氨基或氨基阿维菌素B1a化合物,及其在制备杀虫剂中的应用,属于农药技术领域。
背景技术
阿维菌素作为一类重要的十六元大环内酯抗生素,具有活性高、杀虫谱广、选择性强和低毒安全等优点,作为高效生物源杀虫、杀螨剂广泛应用于农、林和养殖业。但随着长期及不合理使用,害虫抗性提高,致使阿维菌素用药剂量不断增加,对阿维菌素的结构进行合理改造,寻找更高效的阿维菌素类衍生物是当前的研究热点。
烟碱类杀虫剂是继有机磷类、氨基甲酸酯类、拟除虫菊酯类杀虫剂之后第四代杀虫剂。其作为乙酰胆碱酯酶受体抑制剂,化学结构新颖、生物活性独特,对哺乳动物安全,杀虫高效、选择性较好,且与传统的农药之间不存在交互抗性,具有广阔的市场前景。
在农药增效减量的大背景下,将烟碱杀虫剂的有效结构片段与阿维菌素拼合,开发出活性高、抗虫谱广、毒性低、用量少的新型杀虫剂意义重大。
发明内容
本发明的目的在于提供一种烟碱甲氨基或氨基阿维菌素B1a化合物。
本发明的另一目的在于提供上述烟碱甲氨基或氨基阿维菌素B1a化合物的制备方法。
本发明的再一目的在于提供上述烟碱甲氨基或氨基阿维菌素B1a化合物在制备杀虫剂的用途。
以下对本发明进行详细描述。
本发明提供的烟碱甲氨基或氨基阿维菌素B1a化合物,结构如下式所示:
式中,R独立选自H,CH3;Ar独立选自
具体为:
本发明还提供了上述化合物的制备方法包括以下步骤:
所述R独立选自H,CH3;Ar独立选自 所述溶剂选自DMF,DMSO,1,4-二氧六环,N-甲基吡咯烷酮;所述碱选自KOH,无水磷酸钾,Cs2CO3;所述1,2-二胺选自1,2-环己二胺,乙二胺,1,1’-联萘-2,2’-二胺。
本发明的烟碱甲氨基或氨基阿维菌素B1a化合物,在制备杀虫剂中的用途。
具体实施方式
通过以下实施例进一步举例说明本发明,但应注意本发明的范围并不受这些实施例的任何限制。
实施例1
化合物(1)的制备
氮气保护下,将8.86g(10mmol)的甲氨基阿维菌素B1a溶于50mLDMF中,加入8.48g(40mmol)无水磷酸钾,搅拌,滴加798mg(10.5mmol)的CS2,室温反应4h,加入190mg(1mmol)的CuI和228mg(2mmol)的1,2-环己二胺,搅拌,加热至100℃,滴加2.81g(11mmol)的吡虫啉,保温反应12h,冷却,过滤,减压浓缩,硅胶柱层析(氯仿:甲醇60:1)纯化,得到化合物(1),收率83.3%;1HNMR(400MHz,CDCl3)δ:8.72(m,1H),7.94(m,1H),7.78(s,1H),7.56(m,1H),5.86(s,1H),5.72-5.78(m,3H),5.56(d,J=4Hz,1H),5.35-5.44(m,4H),4.78(d,J=4Hz,1H),4.69(s,2H),4.40-4.42(m,1H),4.30-4.31(m,1H),3.83-4.08(m,8H),3.52-3.71(m,1H),3.29-3.49(m,11H),2.89(m,4H),2.52(m,1H),2.00-2.38(m,4H),1.98(m,2H),1.88(s,3H),1.07-1.50(m,12H),0.86-1.07(m,20H)。
实施例2
化合物(2)的制备
将8.86g(10mmol)的甲氨基阿维菌素B1a溶于50mL的DMSO中,加入2.24g(40mmol)KOH,搅拌,滴加836mg(11mmol)的CS2,室温反应6h,然后氮气保护下,加入190mg(1mmol)的CuI和132mg(2.2mmol)的乙二胺,搅拌,加热至105℃,滴加2.77g(11mmol)的噻虫啉,保温反应16h,冷却,过滤,减压浓缩,硅胶柱层析(氯仿:甲醇65:1)纯化,得到化合物(2),收率76.4%;1HNMR(400MHz,CDCl3)δ:8.41-8.52(m,1H),7.81-7.92(m,1H),7.50-7.57(m,1H),5.86(s,1H),5.72-5.78(m,3H),5.56(d,J=4Hz,1H),5.35-5.44(m,4H),4.78(d,J=4Hz,1H),4.69(s,2H),4.39-4.42(m,1H),4.30-4.31(m,1H),3.82-4.08(m,10H),3.51-3.72(m,3H),3.28-3.49(m,11H),2.52(m,1H),2.01-2.38(m,6H),1.88(s,3H),1.07-1.51(m,12H),0.86-1.06(m,20H)。
实施例3
化合物(3)的制备
将8.86g(10mmol)的甲氨基阿维菌素B1a溶于50mL的N-甲基吡咯烷酮中,加入13.0g(40mmol)Cs2CO3,搅拌,滴加836mg(11mmol)的CS2,室温反应5h,然后氮气保护下,加入190mg(1mmol)的CuI和568mg(2mmol)的1,1’-联萘-2,2’-二胺,搅拌,加热至105℃,滴加3.20g(11mmol)的噻虫嗪,保温反应14h,冷却,过滤,减压浓缩,硅胶柱层析(氯仿:甲醇60:1)纯化,得到化合物(3),收率76.4%;1H NMR(400MHz,CDCl3)δ:7.46(s,1H),5.86(s,1H),5.72-5.78(m,3H),5.56(d,J=4Hz,1H),5.35-5.45(m,4H),4.91(s,2H),4.87(s,2H),4.79(d,J=4Hz,1H),4.73(s,2H),4.69(s,2H),4.40-4.42(m,1H),4.29-4.31(m,1H),3.83-4.07(m,8H),3.52-3.70(m,1H),3.29-3.50(m,11H),2.99(s,3H),2.52(m,1H),2.01-2.38(m,4H),1.89(s,3H),1.07-1.50(m,12H),0.86-1.07(m,20H)。
实施例4
化合物(4)的制备
将8.86g(10mmol)的甲氨基阿维菌素B1a溶于50mLDMF中,加入8.48g(40mmol)无水磷酸钾,搅拌,滴加836mg(11mmol)的CS2,室温反应4h,然后氮气保护下,加入190mg(1mmol)的CuI和228mg(2mmol)的1,2-环己二胺,搅拌,加热至105℃,滴加2.75g(11mmol)的噻虫胺,保温反应13h,冷却,过滤,减压浓缩,硅胶柱层析(氯仿:甲醇60:1)纯化,得到化合物(4),收率80.1%;1H NMR(400MHz,CDCl3)δ:9.13(s,1H),7.93(s,1H),7.57(s,1H),5.86(s,1H),5.72-5.78(m,3H),5.56(d,J=4Hz,1H),5.35-5.44(m,4H),4.78(d,J=4Hz,1H),4.69(s,2H),4.46(m,2H),4.40-4.42(m,1H),4.30-4.31(m,1H),3.82-4.08(m,8H),3.52-3.71(m,1H),3.28-3.49(m,11H),2.78(s,3H),2.52(m,1H),2.00-2.39(m,4H),1.89(s,3H),1.07-1.51(m,12H),0.86-1.07(m,20H)。
实施例5
化合物(5)的制备
将8.86g(10mmol)的甲氨基阿维菌素B1a溶于50mLDMSO中,加入8.48g(40mmol)无水磷酸钾,搅拌,滴加836mg(11mmol)的CS2,室温反应5h,然后氮气保护下,加入190mg(1mmol)的CuI和568mg(2mmol)的1,1’-联萘-2,2’-二胺,搅拌,加热至105℃,滴加2.87g(11mmol)的氯噻啉,保温反应15h,冷却,过滤,减压浓缩,硅胶柱层析(氯仿:甲醇60:1)纯化,得到化合物(5),收率82.7%;1H NMR(400MHz,CDCl3)δ:8.16(s,1H),7.47(s,1H),5.86(s,1H),5.72-5.78(m,3H),5.56(d,J=4Hz,1H),5.35-5.44(m,4H),4.79(d,J=4Hz,1H),4.69(s,2H),4.63(s,2H),4.40-4.42(m,1H),4.30-4.31(m,1H),3.80-4.08(m,10H),3.52-3.71(m,3H),3.29-3.49(m,11H),2.52(m,1H),2.00-2.39(m,4H),1.88(s,3H),1.07-1.50(m,12H),0.86-1.07(m,20H)。
实施例6
化合物(6)的制备
将8.72g(10mmol)的氨基阿维菌素B1a溶于50mLDMF中,加入8.48g(40mmol)无水磷酸钾,搅拌,滴加836mg(11mmol)的CS2,室温反应5h,然后氮气保护下,加入190mg(1mmol)的CuI和568mg(2mmol)的1,1’-联萘-2,2’-二胺,搅拌,加热至105℃,滴加3.20g(11mmol)的噻虫嗪,保温反应13h,冷却,过滤,减压浓缩,硅胶柱层析(氯仿:甲醇60:1)纯化,得到化合物(6),收率79.8%;1H NMR(400MHz,CDCl3)δ:7.46(s,1H),5.86(s,1H),5.72-5.78(m,3H),5.56(m,1H),5.35-5.44(m,4H),5.09(br.s,1H),4.90(s,2H),4.87(s,2H),4.74-4.78(m,3H),4.69(s,2H),4.40-4.42(m,1H),4.30-4.31(m,1H),3.83-4.08(m,8H),3.52-3.71(m,1H),3.29-3.49(m,8H),2.99(s,3H),2.52(m,1H),2.00-2.38(m,4H),1.88(s,3H),1.07-1.50(m,12H),0.86-1.07(m,20H)。
实施例7
杀虫剂对桃蚜的室内毒力测定
采用蚕豆苗饲喂繁殖桃蚜。将桃蚜接种至株高约5cm的蚕豆苗上,蚕豆苗置于由孔径0.15mm的尼龙网制成的养虫笼内,在恒温气候室内饲养,饲养温度(23±1)℃,相对湿度60%,光照周期16h:8h(L:D)。
将供试杀虫剂溶于DMF配成母液,用蒸馏水将供试药剂稀释成6个梯度浓度的溶液。移取0.5mL药液于内壁面积为48.6cm2的闪烁瓶中,充分滚动均匀,待溶剂完全挥发后制得相应剂量的药膜管。选取大小一致的无翅成蚜转移至药膜管中,每一剂量处理50头,重复4次,以蒸馏水为对照。将药膜管置于光照培养箱中,温度为(27±2)℃,相对湿度为70%-80%,光周期为14h:10h(L:D)。于处理后24h检查死虫数,当毛笔尖轻触虫体不动时,视为死亡。用统计软件SPSS19.0进行室内毒力测定,计算半致死用量(LR50)。结果显示,烟碱甲氨基或氨基阿维菌素B1a化合物均有好的杀虫活性(表1)。
表1杀虫剂的LR50
杀虫剂 LR50(g·hm-1) 杀虫剂 LR50(g·hm-1)
化合物(1) 0.722 吡虫啉 1.345
化合物(2) 0.923 噻虫啉 1.527
化合物(3) 0.817 噻虫嗪 1.830
化合物(4) 0.929 噻虫胺 2.552
化合物(5) 1.217 氯噻啉 4.567
化合物(6) 1.035 甲氨基阿维菌素B1a 1.633

Claims (3)

1.一种烟碱甲氨基或氨基阿维菌素B1a化合物,结构如下式所示:
2.根据权利要求1所述的一种烟碱甲氨基或氨基阿维菌素B1a化合物,其制备方法包括以下步骤:
所述R,Ar与上述权利要求1中化合物一致;所述溶剂选自DMF,DMSO,1,4-二氧六环,N-甲基吡咯烷酮;所述碱选自KOH,无水磷酸钾,Cs2CO3;所述1,2-二胺选自1,2-环己二胺,乙二胺,1,1’-联萘-2,2’-二胺。
3.根据权利要求1所述的一种烟碱甲氨基或氨基阿维菌素B1a化合物在制备杀虫剂中的应用。
CN202211065978.7A 2022-09-01 2022-09-01 一种烟碱甲氨基或氨基阿维菌素B1a化合物及其制备方法和应用 Active CN115403644B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211065978.7A CN115403644B (zh) 2022-09-01 2022-09-01 一种烟碱甲氨基或氨基阿维菌素B1a化合物及其制备方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211065978.7A CN115403644B (zh) 2022-09-01 2022-09-01 一种烟碱甲氨基或氨基阿维菌素B1a化合物及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN115403644A CN115403644A (zh) 2022-11-29
CN115403644B true CN115403644B (zh) 2024-04-05

Family

ID=84162773

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211065978.7A Active CN115403644B (zh) 2022-09-01 2022-09-01 一种烟碱甲氨基或氨基阿维菌素B1a化合物及其制备方法和应用

Country Status (1)

Country Link
CN (1) CN115403644B (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2214092A (en) * 1991-09-04 1993-03-11 Merck & Co., Inc. 13 beta-O-methoxymethyl-22,23-dihydro avermectin B1a/B1b aglycone as a superior antiparasitic agents
CN1302805A (zh) * 2000-12-06 2001-07-11 南开大学 5-阿(依)维菌素B1a酯的合成及生物活性
WO2004067543A1 (en) * 2003-01-31 2004-08-12 Syngenta Participations Ag Avermectin and avermectin monosaccharide derivatives substituted in the 4”- or 4’-position having pesticidal properties
WO2005097816A1 (en) * 2004-04-07 2005-10-20 Syngenta Participations Ag Avermectin and avermectin monosaccharide substituted in the 4”- and 4’- position respectively

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2214092A (en) * 1991-09-04 1993-03-11 Merck & Co., Inc. 13 beta-O-methoxymethyl-22,23-dihydro avermectin B1a/B1b aglycone as a superior antiparasitic agents
CN1302805A (zh) * 2000-12-06 2001-07-11 南开大学 5-阿(依)维菌素B1a酯的合成及生物活性
WO2004067543A1 (en) * 2003-01-31 2004-08-12 Syngenta Participations Ag Avermectin and avermectin monosaccharide derivatives substituted in the 4”- or 4’-position having pesticidal properties
WO2005097816A1 (en) * 2004-04-07 2005-10-20 Syngenta Participations Ag Avermectin and avermectin monosaccharide substituted in the 4”- and 4’- position respectively

Also Published As

Publication number Publication date
CN115403644A (zh) 2022-11-29

Similar Documents

Publication Publication Date Title
ES2370534T3 (es) Agente para el control de plagas que contiene un derivado de piridil-metanamina novedoso o una de sus sales.
CH616662A5 (zh)
EP0470600B1 (de) Naphthylalkylaminopyrimidin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Schädlingsbekämpfungsmittel
EP0639569A1 (en) Novel heterocyclic compound
JP2696342B2 (ja) アミジン誘導体、その製造方法及び殺ダニ剤・農園芸用殺菌剤
CN109053406A (zh) β-紫罗兰酮衍生的查儿酮类化合物及其制备方法和应用
CN103214461B (zh) 一种喹啉衍生物及其用途
CN107382848A (zh) 一种烟酰胺化合物及其制备方法和应用
CN115403644B (zh) 一种烟碱甲氨基或氨基阿维菌素B1a化合物及其制备方法和应用
CN108191629A (zh) 一种阿魏酸衍生物及其应用
CN114605298B (zh) 一种含氟苯甲酰硫脲类杀虫杀螨剂
KR920001469B1 (ko) 테트라히드로피리미딘 유도체
CN112010836B (zh) 含芳基联吡啶氧基结构的2-取代基咪唑烷衍生物及其制备方法和用途
CN106349223B (zh) 含嘧啶硫醚结构的吡唑肟醚化合物的制备方法和应用
JPH08245322A (ja) 殺虫殺菌組成物
CN114805197B (zh) 一种含氟吡啶酰基脲类杀虫杀螨剂
CN111039878B (zh) 一种4-氨基喹唑啉苯醚类化合物及其应用
CN108148049B (zh) 一种三嗪酮结构的5-吡唑酰胺类化合物制备方法与应用
EP0033580B1 (en) Novel benzenamines, their preparation and fungicide and anticoccidial compositions containing them
CN111925365B (zh) 含取代1,3,5-噁二嗪单元的吡啶衍生物的制备方法与用途
CN111675699B (zh) 一种含2-取代基咪唑烷结构单元的吡唑衍生物的制备方法与应用
CN111909145B (zh) 含吡啶联取代苯氧基单元的2-取代基-1,3-噻唑烷的制备与用途
US4265901A (en) 2-Oxybenzimidazoline compounds
CN111978243B (zh) 草酸单酯类衍生物的合成及其应用
CN116589430A (zh) 一种含氟酰胺噻唑烷酯类化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant